Company news
Pharming Group Nv (EURONEXT:PHARM) news
Every Pharming Group Nv press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term...
July 30, 2026
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
July 16, 2026
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
June 4, 2026
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
June 2, 2026
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
May 28, 2026
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the Euro...
May 22, 2026
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in...
May 7, 2026
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan an...
May 7, 2026
Pharming Group to report first quarter 2026 financial results and provide business update on May 7
April 23, 2026
Pharming Group announces the 2026 Annual General Meeting of Shareholders
April 16, 2026
Pharming Group to participate in April investor conferences
April 7, 2026
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
April 2, 2026
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years...
March 27, 2026
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
March 24, 2026
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with posit...
March 12, 2026
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
February 26, 2026
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
February 3, 2026
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
February 1, 2026
Pharming Group reports preliminary 2025 revenues and announces Investor Day
January 8, 2026
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
December 8, 2025
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
November 6, 2025
Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
October 30, 2025
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
October 23, 2025
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
October 20, 2025
Pharming Group provides update on previously announced G&A expense reduction plan
October 6, 2025
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APD...
October 1, 2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
September 18, 2025
Pharming Group promoted to the Euronext AMX® index
September 10, 2025
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
September 2, 2025
Pharming Group to participate in August investor conference
August 4, 2025
Pharming Group reports second quarter and first half 2025 financial results and provides business update
July 31, 2025
Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
July 17, 2025
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain ...
June 24, 2025
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
June 11, 2025
Pharming Group to participate in June investor conferences
May 28, 2025
Pharming Group reports first quarter 2025 financial results and provides business update
May 8, 2025
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
April 30, 2025
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
April 25, 2025
Pharming Group to report first quarter 2025 financial results on May 8
April 24, 2025
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
April 23, 2025